EUCTR2007-004888-22-BE进行中（未招募）1 期
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have confirmed diagnosis, according to the Revised European American Lymphoma/World Health Organization [REAL/WHO] classification, of the following B-cell lymphomas:
- •1.Follicular lymphoma (FL)
- •2.Marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT)
- •3.Diffuse large B-cell lymphoma (DLBCL)
- •4.Mantle cell lymphoma (MCL), OR
- •5.Hodgkin lymphoma (HL)
- •Patients must have progressed after at least 2 prior therapies (autologous stem cell transplantation is considered as 1 therapy):
- •1.Patient must receive at least one prior therapy with a rituximab containing regimen if it is indicated as the standard of care.
- •2.If patient received autologous stem cell transplantation, patient must have received at least 1 prior systemic therapy
- •3.If patient did not receive autologous stem cell transplantation, patient must have received at least 2 prior systemic therapies
- •Patients who received autologous stem cell transplantation:
- •1.Must be at least 12 weeks post-transplant prior to study drug, AND
- •2.Must have recovered fully from the side effects of such treatment prior to beginning study treatment.
- •Patients who have NOT received autologous stem cell transplantation:
- •1.Must be ineligible for the autologous stem cell transplantation, OR
- •2.If eligible, patients chose not to receive stem cell transplant
- •Patients must have discontinued any previous anticancer and investigational therapy including radiation therapy for at least 21 days prior to study drug, and must have recovered fully from the side effects of such treatment prior to beginning study drug.
- •Patients must have discontinued any previous monoclonal antibody (except rituximab) or radioimmunotherapy administration for at least 60 days prior to study drug, and are confirmed either have no response to that therapy or have disease progression after the treatment. Patients must have recovered fully from the side effects of that treatment prior to beginning study treatment.
- •For patients who received rituximab containing regimen, rituximab should be discontinued for at least 28 days prior to study drug, are confirmed to either have no response or have disease progression after rituximab treatment, and must have recovered fully from the side effects of such treatment prior to beginning study drug.
- •Patients must not have undergone major surgery within 30 days prior to study drug, and must have recovered fully from the side effects of any major or minor surgical procedures prior to study treatment.
- •Patients must be ? 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have been treated with any anti-CD40 antibody
- •Patients who have received prior allogeneic stem cell transplant
- •Patients who have had a prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration
- •Patients who are taking systemic corticosteroids, except for a dose up to 100 mg of hydrocortisone or equivalent as premedication administered prior to certain medications or blood products
- •Patients who have current drug or alcohol abuse
- •Patients who have history or clinical evidence of central nervous system, meningeal, or epidural disease including brain metastasis
- •Impaired cardiac function or clinically significant cardiac disease, including any one of the following:
- •1.New York Heart Association Class III or IV cardiac disease, including preexisting clinically significant arrhythmia, congestive heart failure, or cardiomyopathy
- •2.Angina pectoris = 3 months prior to starting study drug
- •3.Acute MI = 3 months prior to starting study drug
- •4.Other clinically significant heart disease (e.g., uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Patients who have history of pancreatic disease (e.g., acute or chronic pancreatitis, etc.) or any surgery of the pancreas
- •Patients who have gallbladder stone, cystic fibrosis, or any other risk factors that may increase the risk of pancreatitis
- •Patients who have history of active infection (viral, bacterial, or fungal) requiring systemic therapy within 4 weeks prior to enrollment. Prophylactic antibiotics and anti-viral therapies are permitted
研究者
相似试验
进行中（未招募）
不适用
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapiesEUCTR2007-004888-22-DEovartis Pharma Services AG230
进行中（未招募）
1 期
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103EUCTR2007-004888-22-GBovartis Pharma Services AG
进行中（未招募）
不适用
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapies. - CHCD122A2103EUCTR2007-004888-22-FRovartis Pharma AG230
进行中（未招募）
不适用
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 17.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-BEovartis Pharma AG91
进行中（未招募）
1 期
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 15.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-FRovartis Pharma AG91